TY  - BOOK
AU  - Desai, Sanjal
TI  - Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naive chronic lymphocytic leukemia: a phase 2 study
SN  - 1026-8022
PY  - 2021///
KW  - *Leukemia, Lymphocytic, Chronic, B-Cell
KW  - Antibodies, Monoclonal, Humanized/tu [Therapeutic Use]
KW  - Antineoplastic Combined Chemotherapy Protocols/ae [Adverse Effects]
KW  - Humans
KW  - Immunotherapy
KW  - Leukemia, Lymphocytic, Chronic, B-Cell/di [Diagnosis]
KW  - Leukemia, Lymphocytic, Chronic, B-Cell/dt [Drug Therapy]
KW  - Treatment Outcome
KW  - Washington Cancer Institute
KW  - Journal Article
N2  - High-risk cytogenetics and minimal residual disease (MRD) after chemoimmunotherapy (CIT) predict unfavorable outcome in chronic lymphocytic leukemia (CLL). This phase 2 study investigated risk-adapted CIT in treatment-naive CLL (NCT01145209). Patients with high-risk cytogenetics received induction with fludarabine, cyclophosphamide, and ofatumumab. Those without high-risk cytogenetics received fludarabine and ofatumumab. After induction, MRD positive (MRD+) patients received 4 doses of ofatumumab consolidation. MRD negative (MRD-) patients had no intervention. Of 28 evaluable for response, all responded to induction and 10 (36%) achieved MRD-. Two-year progression-free survival (PFS) was 71.4% (CI95, 56.5-90.3%). There was no significant difference in median PFS between the high-risk and the standard-risk groups. Ofatumumab consolidation didn't convert MRD + to MRD-. In the MRD + group, we saw selective loss of CD20 antigens during therapy. In conclusion, risk-adapted CIT is feasible in treatment-naive CLL. Ofatumumab consolidation didn't improve depth of response in MRD + patients. Loss of targetable CD20 likely reduces efficacy of consolidation therapy
UR  - https://dx.doi.org/10.1080/10428194.2021.1888379
ER  -